Results 191 to 200 of about 693,900 (279)

SLFN11 expression as a marker of small cell lung cancer vulnerability to combined PARP inhibitors and immune checkpoint inhibitors during maintenance. [PDF]

J Thorac Dis
Pujol JL.
europepmc   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

Clinical application of PARP inhibitors and emerging strategies to overcome resistance: a pan-cancer perspective. [PDF]

Biomark Res
Xiang J, Li J, Guo Z, Wu J, Ma D, Xu H, Shang T, Pu P, Cong L, Zhou R, Wang X, Yu Y, Liu J.   +12 more
europepmc   +1 more source

The PRIME trial: An investigator‐initiated, multicentre, phase II study of the poly(ADP‐ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)‐mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes

British Journal of Haematology, EarlyView.
Rory M. Shallis, Jennifer VanOudenhove, Namrata Chandhok, Justin Watts, Deepa Jeyakumar, Daniel R. Reed, Jan Phillip Bewersdorf, Diane Durecki, Scott Boerner, Richard F. Little, Steven D. Gore, Jing Li, Xun Bao, Li Chen, Sayak Ghatak, Thomas Prebet, Ranjit S. Bindra, Amer M. Zeidan, Stephanie Halene   +18 more
wiley   +1 more source

Nicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small‐Cell Lung Cancer Models

Cancer Science, EarlyView.
Dietary NA restriction converts the effect of NAMPT inhibition from cytostatic to cytotoxic in SCLC in vivo. ABSTRACT Small‐cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. We previously showed that nicotinic acid riboside (NAR) sustains NAD biosynthesis in vivo and compensates for NAMPT inhibition in SCLC models ...
Kyoji Tsurumi, Miyuki Nomura, Mai Ouchi, Shigehiro Yagishita, Naohiko Kikuchi, Taku Sato, Mami Morita, Yoji Yamashita, Kayoko Hayashi, Tomoyoshi Soga, Akinobu Hamada, Tatsuro Fukuhara, Nobuhiro Tanuma   +12 more
wiley   +1 more source

Progression-Free Survival with PARP Inhibitors According to Clinical Risk in Patients with Ovarian Cancer: An Indirect Comparison Using Reconstructed Data. [PDF]

Oncol Res
Gasperoni L, Del Bono L, Farolfi A, Messori A, Damuzzo V.   +4 more
europepmc   +1 more source

Leveraging venetoclax‐induced autophagy to enhance AUTAC‐mediated Mcl1 degradation and overcome resistance in acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Ahmed M. Elshazly, Nayyerehalsadat Hosseini, Janakiram R. Vangala, Xiaoyan Hu, Steven Grant, Senthil K. Radhakrishnan   +5 more
wiley   +1 more source

Decreased Expression by a Chemically Modified siRNA to PTBP1 Seriously Affects Warburg Effect in Colorectal Cancer Cells

Cancer Science, EarlyView.
Chemically modified siR‐PTBP1 disrupts the Warburg effect by reprogramming pyruvate kinase splicing from PKM2 to PKM1. This metabolic shift activates the TCA cycle, increases ATP production, and excessive ROS generation, and ultimately induces apoptotic cell death in colorectal cancer cells.
Keita Matsumoto, Hirokatsu Hayashi, Yoshihisa Tokumaru, Seito Fujibayashi, Noriki Mitsui, Masahide Endo, Takeshi Horaguchi, Yuji Hatanaka, Ryoma Yokoi, Chika Mizutani, Masashi Kuno, Masahiro Fukada, Ryuichi Asai, Itaru Yasufuku, Yuta Sato, Jesse Yu Tajima, Yoshihiro Tanaka, Remi Nakashima, Yukihiro Akao, Nobuhisa Matsuhashi   +19 more
wiley   +1 more source

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer. [PDF]

Curr Treat Options Oncol
Weiner-Gorzel K, McSorley L, Walshe JM.
europepmc   +1 more source

The DNA/RNA Helicase SETX Maintains R‐Loop Homeostasis to Promote Chemoresistance in Ovarian Cancer

Cancer Science, EarlyView.
SETX maintains R‐loop homeostasis by resolving excessive R‐loops, thereby promoting tumor initiation and chemoresistance. Deficiency of SETX leads to accumulation of unsolved pathological R‐loops, resulting in irreparable DNA damage and ultimately leading to tumor suppression and chemosensitivity.
Zi‐Wei Hu, Tu‐Nan Xu, Zi‐Ying Wang, Xin Zheng, Duan‐Yong Feng, Xiao‐Min Wang, Er‐Suo Jin, Ming Ren, Xiao‐Min Yang, Xian‐Chao Zhang, Xuan Che, Wei‐Wei Pan, Zha‐Jun Zhan, Shu‐Qun Cheng   +13 more
wiley   +1 more source